Skip to main content

Department of Urology

Paramita M. Ghosh, M.Sc., Ph.D. View profile as PDF

Clinical Interests

My current research concentrates on the study of signal transduction pathways involved in prostate cancer development and progression. This includes studies on the EGFR family of receptor tyrosine kinases, leading to the PI3K/Akt pathway and finally to the mTOR signaling pathway. In particular, I investigate the interaction of these pathways with the androgen receptor. My research involves identification of significant therapeutic targets, as well as studying the effects of inhibitors of those targets both in vitro as well as in animal models. I am currently funded to study drug combinations that target parallel signaling pathways and in combination, appear to be highly effective in inhibiting the progression of prostate cancer.

Title:

Associate Professor

Specialty:

Cancer, Urologic Oncology, Urology

Department:

Urology

Division:

Urology

Center/Program Affiliation:

Other Languages:

Bengali

Education:

M.Sc., Jadavpur University, Calcutta, 1989
Ph.D., Rensselaer Polytechnic Institute, Troy, New York, 1994
B.Sc., Jadavpur University, Calcutta, 1987

Fellowships:

University of Texas Health Science Center, San Antonio, Texas, 1994-2000

Professional Memberships:

American Association for Cancer Research
American Association for the Advancement of Science
American Urological Association
The Society for Basic Urologic Research

Select Recent Publications:

Savoy RM, Ghosh PM. Linking inflammation and neuroendocrine differentiation: the role of macrophage migration inhibitory factor-mediated signaling in prostate cancer. Endocr Relat Cancer. 2013 May 21;20(3):C1-4

Savoy RM, Ghosh PM. The changing roles of steroid nuclear receptors with prostate cancer progression. Endocr Relat Cancer. 2013 Jul 4;20(4):C9-11

Savoy RM, Ghosh PM. The dual role of filamin A in cancer: can't live with (too much of) it, can't live without it. Endocr Relat Cancer. 2013 Nov 4;20(6):R341-56. doi: 10.1530/ERC-13-0364. Print 2013 Dec.

Mooso BA, Vinall RL, Tepper CG, Savoy RM, Cheung JP, Singh S, Siddiqui S, Wang Y, Bedolla RG, Martinez A, Mudryj M, Kung HJ, Devere White RW, Ghosh PM. Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. Endocr Relat Cancer. 2012 Nov 9;19(6):759-77

Ghosh PM. What controls PTEN and what it controls (in prostate cancer). Asian J Androl. 2012 Jan;14(1):130-1.  Epub 2011 Sep 26.

Jathal MK, Chen L, Mudryj M, Ghosh PM. Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block. Immunol Endocr Metab Agents Med Chem. 2011 Jun;11(2):131-149.

Ghosh, P.M.,  Shu, Z.J., Zhu, B., Lu, Z., Ikeno, Y., Barnes, J.L., Yeh, C.K., Zhang, B.K., Katz, M.S. and Kamat, A. β-Adrenergic Receptor Signaling Increases Lipid Accumulation In Liver During Aging. Journal of Endocrinology 2012 Jun;213(3):251-61

Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res. 2011;1(4):542-61. Epub 2011 Mar 28.

Vinall RL, Mahaffey CM, Davis RR, Luo Z, Gandour-Edwards R, Ghosh PM, Tepper CG, de Vere White RW. Dual blockade of PKA and NF-?B inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. Horm Cancer. 2011 Aug;2(4):224-38.

Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L, Vinall RL, deVere White RW, Ghosh PM. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res. 2011 Oct 1;17(19):6218-28. Epub 2011 Aug 15.